（来源：邯郸日报） 转自：邯郸日报 本报讯（韩艳萍）1月6日，邯郸现代中药基地产业园项目生产车间，在先进数字化中药提取生产线上， 3名员工通过电脑熟练地操控着20余台智能化中药提取浓缩设备：只需轻轻按动功能按键，6道工序就全 部自动化完成。 "中药提取是保障中药产品内在质量最关键的环节。过去，靠人工完成这些步骤，产品质量稳定性差、 生产效率低，是制约行业的难题。"邯郸制药股份有限公司董事长陈致慜说。为了攻破这个难题，该公 司投入近5000万元新上了先进数字化中药提取生产线，并配置了4台智能化中药提取罐装设备。有了这 些生产线和设备，改变了过去仅靠人工经验控制质量的原始中药生产过程，企业完成了从传统工艺到智 能化操作和监测的转换，实现了中药制剂自动化、检测智能化、实时监控动态化，目前在国内中药制药 领域属于首创，创新性较强，处于国内领先水平。 2025年以来，邯山区大力实施科技创新驱动战略，通过政策引导、搭建平台、引智赋能、扶优培强，推 动企业数智化改造，扎实推进高新技术企业和科技型中小企业"双倍增"计划，构建"科技型中小企业— 国家科技型中小企业—高新技术企业—科技领军企业"的全链条培育体系。 该区一方面引导 ...

作为人才培养的主阵地，高校传统的育人模式已较难适应经济社会高质量发展的要求。产教融合作为破 解人才供需矛盾的主抓手，已成为推动高校创新育人模式的新力量。 江西中医药大学现代产业学院以产教融合为引擎，通过教育链、人才链与产业链、创新链的有机融合， 以优化育人内容、变革育人模式、创新育人实践为抓手，培养更多高素质应用型、创新型优秀人才，取 得实效。 基于产教融合 优化育人内容 学院聚焦产业转型升级、创新产教融合新模式，联合行业企业、产业协会等社会力量，结合行业需求与 技术发展，特别是社会对人才的知识与能力要求，制定并完善基于产教融合的课程标准，规划和设计课 程教学内容，开发"项目化课程""模块化课程"，将企业真实案例、技术难题、工艺流程等转化为教学内 容和项目库，有效链接课堂与企业，促进企业教师与学生的有效沟通，深化校企协同、产教融合的育人 效果。 打造产教融合课程。学院联合共建单位江西赫柏康华制药设备有限公司，依托企业经验丰富的技术人员 与校内专业教师团队，共同设计开发《现代中药制药装备现状及发展》课程，以鲜活生动的教学方式， 围绕现代中药制药装备的技术构成、行业现状及其应对策略与措施进行剖析，引导学生全面领略 ...

据交易所数据显示，12月16日，苏轩堂(SXTC)盘中上涨9.93%，截至03:33，报1.55美元/股，成交131.76 万美元，总市值1.80亿美元。 财务数据显示，截至2025年03月31日，苏轩堂收入总额174.09万美元，同比减少9.73%；归母净利 润-330.37万美元，同比减少6.62%。 资料显示，中国苏轩堂药业股份有限公司(简称"中国苏轩堂") 一家创新型的中药制药公司,专注于中药 饮片产品尤其是现代中药饮片(直接口服及泡服饮片)的研发、生产和销售。中药饮片是一种经加工可以 服用的传统中药。几千年以来,中药饮片被中国人广泛使用。 本文源自：市场资讯 作者：行情君 ...

财务数据显示，截至2025年03月31日，苏轩堂收入总额174.09万美元，同比减少9.73%；归母净利 润-330.37万美元，同比减少6.62%。 作者：行情君 据交易所数据显示，12月15日，苏轩堂(SXTC)开盘上涨3.68%，截至22:30，报1.41美元/股，成交2.5万 美元，总市值1.64亿美元。 本文源自：市场资讯 资料显示，中国苏轩堂药业股份有限公司(简称"中国苏轩堂") 一家创新型的中药制药公司,专注于中药 饮片产品尤其是现代中药饮片(直接口服及泡服饮片)的研发、生产和销售。中药饮片是一种经加工可以 服用的传统中药。几千年以来,中药饮片被中国人广泛使用。 ...

Core Viewpoint - The 21st century is witnessing a shift in life sciences research from Western to Eastern methodologies, aligning with Traditional Chinese Medicine (TCM) principles of holistic regulation and syndrome differentiation [1] Group 1: Research and Development Achievements - Professor Wu Yiling has developed the "Vascular Theory" through national research projects, leading to significant breakthroughs in the prevention and treatment of vascular diseases [1] - Three patented traditional Chinese medicines, known as "Tongluo Sanbao" (Tongxinluo Capsules, Shensongyangxin Capsules, and Qiliqiangxin Capsules), have been developed under this theory, demonstrating solid scientific evidence and clinical efficacy in treating cardiovascular diseases [1][5] Group 2: Clinical Research Outcomes - Tongxinluo Capsules have shown to stabilize vulnerable plaques and reduce the incidence of vascular events by 36%, with a 30% reduction in cardiovascular mortality risk and a 74% decrease in one-year recurrence risk, as published in JAMA [3] - Shensongyangxin Capsules have been proven to effectively treat ventricular premature beats and atrial fibrillation, outperforming conventional drugs in certain studies, and have shown a 40.4% reduction in atrial fibrillation recurrence risk post-ablation [4] - Qiliqiangxin Capsules have significantly reduced the risk of major composite events in chronic heart failure patients by 22%, with notable reductions in hospitalization and cardiovascular death risks [5] Group 3: Global Recognition and Impact - The success of "Tongluo Sanbao" in international markets has established a positive image for TCM and provided a model for its high-quality development [5][6] - The journey of "Tongluo Sanbao" reflects the integration of ancient wisdom with modern scientific research, showcasing TCM's potential to address global cardiovascular health challenges [6]

Core Viewpoint - Alibaba Health and Yiling Pharmaceutical have signed a strategic cooperation agreement to launch a new innovative traditional Chinese medicine product for allergic rhinitis and to collaborate on patient education and chronic disease management [1][2]. Group 1: Product Launch and Clinical Data - Yiling Pharmaceutical's new drug, Qifang Nasal Tablets, for the treatment of persistent allergic rhinitis, will be launched on Alibaba Health's platform in December 2025 and has been included in the national medical insurance directory [1]. - Clinical trials published in the international journal "Ethnopharmacology" show that after four weeks of treatment, the total nasal symptom score improved by 21.8% and eye symptom improvement was 31% compared to the control group [1]. Group 2: Research and Development Investment - Yiling Pharmaceutical has invested over 5 billion yuan in R&D over the past six years, with R&D expenses accounting for nearly 10% of revenue in the first half of 2025 [2]. - The company has conducted over 40 evidence-based medical studies, with results published in prestigious journals such as the "Journal of the American Medical Association" and "Nature" [2]. Group 3: Health Management and Accessibility - Alibaba Health aims to transform allergic rhinitis management from "passive treatment" to "active health management" by utilizing tools such as pollen season alerts and symptom self-assessment [3]. - The company's pharmaceutical supply chain network spans hundreds of cities, ensuring accessibility to quality medical resources, and has integrated over 250,000 contracted healthcare professionals into its service system [2].

Core Viewpoint - The article emphasizes the development strategy of Xixia County in Nanyang, Henan Province, focusing on high-quality industrial growth and employment generation to enhance the wealth and strength of the county during the 14th Five-Year Plan period [3][4]. Industrial Development - Xixia County aims to achieve an industrial economic total exceeding 80 billion yuan in 2024, marking a 64% increase from the end of the 13th Five-Year Plan, with industrial added value growing by 77% and industrial tax revenue increasing by 60% [3]. - The county's industrial economy contributed 62% to the regional GDP, 79% to fiscal revenue, and 42% to employment in the first half of the year [3]. Key Industries and Projects - The county has identified and is cultivating key industries, including special steel materials, with the Henan Longcheng Group as a representative enterprise [5]. - Xixia County's special steel materials industry cluster was included in the Ministry of Industry and Information Technology's list of characteristic industrial clusters for small and medium-sized enterprises [5]. - The county has developed a comprehensive industrial cluster that includes special steel production, iron ore and graphite mining, metallurgy, and green construction [5][6]. Innovation and Technology - Xixia County is focusing on innovation as a key driver for industrial upgrading, with a high coverage rate of R&D activities among industrial enterprises [8]. - The county has established 13 smart factories and is promoting digital transformation across manufacturing enterprises [8]. Green Development - The county is committed to green and low-carbon development, prohibiting the addition of new production capacity in certain industries and promoting green upgrades in steel and metallurgy [9]. - Xixia County has established several national and provincial-level green factories and is actively promoting green supply chain management [9]. Business Environment - The county is enhancing its business environment through administrative reforms, reducing project approval times by over 15%, and implementing a "one-stop" service model [11]. - Xixia County has created a tailored policy package for enterprises and established a system for supporting key enterprises [12]. Future Outlook - Looking ahead to the 15th Five-Year Plan, Xixia County plans to continue nurturing its characteristic industries and accelerate industrial transformation to contribute to high-quality economic development [12].

Core Viewpoint - Tianmu Pharmaceutical has experienced a significant stock price increase, with a 10.00% rise and two trading halts within four days, driven by strong performance expectations and strategic developments in its business segments [1] Group 1: Financial Performance - The company anticipates a substantial increase in net profit for the first half of 2025, projected to grow by 145.94% to 156.75% year-on-year, primarily due to enhanced sales in pharmaceuticals, health products, and medical devices [1] - The latest stock price is 19.80 yuan, with a total market capitalization of 2.411 billion yuan, and a trading volume of 2.57 billion yuan, reflecting a turnover rate of 11.23% [1] Group 2: Strategic Developments - Fourteen products from the company's subsidiary have received re-registration approval, including items like kidney-strengthening tablets, which will positively impact future production and sales [1] - The company is collaborating with Qingdao Huadong Grape Wine to innovate traditional Chinese medicine formulas for beverage derivatives [1] - Tianmu Pharmaceutical is establishing a wellness and retirement industry park focused on hot spring health services, indicating a diversification into the wellness sector [1] Group 3: Market Position and Ownership - The actual controller of the company is the Finance Bureau of Laoshan District, Qingdao, which has sparked market interest regarding potential state-owned enterprise reforms [1] - The company operates in several key sectors, including traditional Chinese medicine, health products, medical devices, state-owned enterprise reform, and the broader health and wellness industry [1]

Core Viewpoint - Su Xuan Tang (SXTC) is experiencing a stock price increase of 3.18%, with a current share price of $1.63 and a total market capitalization of $18.9 million as of August 15 [1] Financial Performance - As of March 31, 2025, Su Xuan Tang reported total revenue of $1.7409 million, representing a year-over-year decrease of 9.73% [1] - The company recorded a net profit attributable to shareholders of -$3.3037 million, which is a year-over-year decline of 6.62% [1] Company Overview - Su Xuan Tang Pharmaceutical Co., Ltd. is an innovative Chinese pharmaceutical company focused on the research, development, production, and sales of traditional Chinese medicine (TCM) decoction pieces, particularly modern TCM decoction pieces for direct oral consumption and infusion [1] - TCM decoction pieces have been widely used in China for thousands of years [1]

Core Viewpoint - Su Xuan Tang (SXTC) experienced a stock price increase of 6.18%, reaching $1.656 per share, with a total market capitalization of $19.2 million as of August 13 [1] Financial Performance - As of March 31, 2025, Su Xuan Tang reported total revenue of $1.7409 million, reflecting a year-on-year decrease of 9.73% [1] - The company's net profit attributable to shareholders was -$3.3037 million, showing a year-on-year decline of 6.62% [1] Company Overview - Su Xuan Tang Pharmaceutical Co., Ltd. is an innovative Chinese pharmaceutical company focused on the research, production, and sales of traditional Chinese medicine (TCM) pieces, particularly modern TCM pieces for direct oral consumption and infusion [1] - Traditional Chinese medicine pieces have been widely used in China for thousands of years [1]